[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,109,786
  • Shares Outstanding, K 82,912
  • Annual Sales, $ 1,731 M
  • Annual Income, $ 682,640 K
  • EBIT $ 892 M
  • EBITDA $ 914 M
  • 60-Month Beta 0.53
  • Price/Sales 3.09
  • Price/Cash Flow 7.35
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 52.23% (-13.83%)
  • Historical Volatility 54.21%
  • IV Percentile 48%
  • IV Rank 38.33%
  • IV High 77.63% on 04/24/26
  • IV Low 36.45% on 01/21/26
  • Expected Move (DTE 4) 5.61 (7.61%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 1,182
  • Volume Avg (30-Day) 310
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 13,673
  • Open Int (30-Day) 10,366
  • Expected Range 68.08 to 79.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.32
  • Number of Estimates 7
  • High Estimate $0.14
  • Low Estimate $-1.21
  • Prior Year $-0.83
  • Growth Rate Est. (year over year) +61.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.18 +16.64%
on 05/01/26
79.91 -7.78%
on 05/08/26
+2.43 (+3.41%)
since 04/08/26
3-Month
61.43 +19.96%
on 03/06/26
79.91 -7.78%
on 05/08/26
-0.99 (-1.33%)
since 02/06/26
52-Week
43.17 +70.68%
on 08/11/25
87.50 -15.78%
on 11/26/25
+31.18 (+73.35%)
since 05/08/25

Most Recent Stories

More News
PTC Therapeutics Q1 Earnings Call Highlights

PTC Therapeutics (NASDAQ:PTCT) reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or PKU.Chief...

PTCT : 73.69 (+14.27%)
PTC Therapeutics: Q1 Earnings Snapshot

PTC Therapeutics: Q1 Earnings Snapshot

PTCT : 73.69 (+14.27%)
PTC Therapeutics Reports With Votoplam Data Already Digested and Guidance Still Unclear

Barchart Research What to Expect from PTCT Earnings PTCT Generated May 6, 2026 Current Price $66.57 EPS Estimate $$-0.31 Consensus Rating Moderate Buy Average Move 7.20% PTC Therapeutics Reports With Votoplam...

PTCT : 73.69 (+14.27%)
PTC Therapeutics to Participate in Upcoming Investor Conferences

WARREN, N.J. , May 4, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:

PTCT : 73.69 (+14.27%)
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose -

PTCT : 73.69 (+14.27%)
PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study

WARREN, N.J. , April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call today, April 28 at 4:30 p.m. ET to share results from the 24-month interim...

PTCT : 73.69 (+14.27%)
PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026

WARREN, N.J. , April 22, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2026 financial...

PTCT : 73.69 (+14.27%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J. , April 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate...

PTCT : 73.69 (+14.27%)
PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

WARREN, N.J. , March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the appointment of Jessica Chutter to its Board of Directors. Ms. Chutter is a highly accomplished...

PTCT : 73.69 (+14.27%)
PTC Therapeutics to Participate at Upcoming Investor Conferences

WARREN, N.J. , Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:

PTCT : 73.69 (+14.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

See More

Key Turning Points

3rd Resistance Point 89.74
2nd Resistance Point 84.83
1st Resistance Point 79.26
Last Price 73.69
1st Support Level 68.77
2nd Support Level 63.86
3rd Support Level 58.29

See More

52-Week High 87.50
Last Price 73.69
Fibonacci 61.8% 70.57
Fibonacci 50% 65.34
Fibonacci 38.2% 60.11
52-Week Low 43.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.